PMID- 32886267
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20240321
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 37
IP  - 10
DP  - 2020 Oct
TI  - Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A 
      Narrative Review.
PG  - 4165-4174
LID - 10.1007/s12325-020-01478-9 [doi]
AB  - According to current guidelines, glucagon-like peptide-1 (GLP-1) receptor 
      agonists are the antidiabetic agent of choice in patients with type 2 diabetes 
      mellitus (T2DM) and established cardiovascular disease (CVD) and are also the 
      preferable antidiabetic agent in patients with T2DM without CVD but with 
      indicators of high cardiovascular risk. A limitation in the use of GLP-1 receptor 
      agonists is that they are delivered by subcutaneous injections. In this context, 
      the development of an orally administered formulation of semaglutide offers an 
      additional option in the management of patients with T2DM. In the present review, 
      we discuss the findings of the main trials that evaluated the safety and efficacy 
      of oral semaglutide. Oral semaglutide appears to be more effective in reducing 
      HbA(1c) levels and body weight than other antidiabetic agents and similarly 
      effective to other GLP-1 receptor agonists. The safety profile of oral 
      semaglutide is also comparable with other members of its class. Even though oral 
      semaglutide did not reduce the incidence of the composite primary endpoint in a 
      randomized controlled trial, a reduction in cardiovascular and all-cause 
      mortality was observed. Therefore, oral semaglutide appears to represent a useful 
      tool in the management of patients with TD2M, particularly those with established 
      CVD or high cardiovascular risk and unwilling to receive injectable GLP-1 
      receptor agonists.
FAU - Sofogianni, Areti
AU  - Sofogianni A
AD  - First Propedeutic Department of Internal Medicine, Medical School, AHEPA 
      Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Tziomalos, Konstantinos
AU  - Tziomalos K
AUID- ORCID: 0000-0002-3172-1594
AD  - First Propedeutic Department of Internal Medicine, Medical School, AHEPA 
      Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 
      ktziomalos@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200904
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor Agonists)
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor
MH  - *Glucagon-Like Peptides/administration & dosage
MH  - Hypoglycemic Agents/administration & dosage
MH  - Glucagon-Like Peptide-1 Receptor Agonists/administration & dosage
MH  - Administration, Oral
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Glucagon-like peptide-1 receptor agonists
OT  - Oral semaglutide
OT  - Type 2 diabetes mellitus
OT  - Weight
EDAT- 2020/09/05 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/07/01 00:00 [received]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - 10.1007/s12325-020-01478-9 [pii]
AID - 10.1007/s12325-020-01478-9 [doi]
PST - ppublish
SO  - Adv Ther. 2020 Oct;37(10):4165-4174. doi: 10.1007/s12325-020-01478-9. Epub 2020 
      Sep 4.